The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics

ConclusionATMOSPHERE will determine whether patients with HF and reduced ejection fraction (particularly those without diabetes) benefit from the addition of a direct renin inhibitor to standard background therapy, including an angiotensin‐converting enzyme inhibitor, beta‐blocker, and a mineralocorticoid receptor antagonist. ATMOSPHERE will also determine whether aliskiren alone is superior to, or at least non‐inferior to, enalapril.

Source: European Journal of Heart Failure - October 28, 2015 Category: Cardiology Authors: Henry Krum, John J.V. McMurray, William T. Abraham, Kenneth Dickstein, Lars Køber, Akshay S. Desai, Scott D. Solomon, Yanntong Chiang, Claudio Gimpelewicz, Bernard Reimund, M. Atif Ali, Georgia Tarnesby, Barry M. Massie, Tags: Original Article Source Type: research